CTLA4 and colorectal neoplasm: Using intravenous delivery of our oncolytic virus-driven T-cell-based combination immunotherapy to target colorectal tumors and CTLA4-positive Treg cells in the microenvironment of the cancer, it has been seen that lung metastases of colorectal tumors have significantly decreased [55].